NVST 📈 Envista Holdings - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29415F1049

NVST: Dental Implants, Orthodontic Products, Dental Equipment, Imaging Systems, Consumables

Envista Holdings Corporation is a leading global dental products company that designs, manufactures, and markets a wide range of innovative dental solutions. The company's product portfolio is diverse and comprehensive, catering to the needs of various dental professionals, including oral surgeons, prosthodontists, periodontists, and general dentists. Its operations are divided into two main segments: Specialty Products & Technologies and Equipment & Consumables. The Specialty Products & Technologies segment focuses on developing and marketing advanced dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics, among other products.

The company's Specialty Products & Technologies segment also offers a range of orthodontic products, including brackets and wires, tubes and bands, archwires, clear aligners, and digital orthodontic treatments. Additionally, it provides software packages, such as DTX Studio Implant, DTX Studio Lab, and DTX Studio Clinic, which are designed to work seamlessly with its imaging products. Envista's products are marketed under several well-known brands, including Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, and AOA. These brands are recognized for their high quality and are widely used by dental professionals around the world.

The Equipment & Consumables segment of Envista Holdings Corporation offers a broad range of dental equipment and supplies, including digital imaging systems, software, and other visualization and magnification systems. This segment also provides endodontic systems and related products, restorative materials, rotary burs, impression materials, bonding agents, and cements, as well as infection prevention products. The company's products in this segment are marketed under brands such as Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes, and are sold to dental offices, clinics, and hospitals globally.

As a relatively new company, Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California. Despite its short history, the company has already established itself as a major player in the global dental products market. Its common stock is listed on the New York Stock Exchange (NYSE) under the ticker symbol NVST, and its ISIN is US29415F1049. The company operates in the Health Care Equipment sub-industry, and its products and services are designed to help dental professionals provide high-quality care to their patients. For more information, visit the company's website at https://envistaco.com.

Additional Sources for NVST Stock

NVST Stock Overview

Market Cap in USD 3,368m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Health Care Equipment
IPO / Inception 2019-09-18

NVST Stock Ratings

Growth 5y -41.0%
Fundamental -37.2%
Dividend -
Rel. Strength Industry -672
Analysts 3.29/5
Fair Price Momentum 16.80 USD
Fair Price DCF 41.00 USD

NVST Dividends

No Dividends Paid

NVST Growth Ratios

Growth Correlation 3m 36.9%
Growth Correlation 12m -44.5%
Growth Correlation 5y -29.5%
CAGR 5y -8.04%
CAGR/Mean DD 5y -0.27
Sharpe Ratio 12m -0.53
Alpha -55.69
Beta 1.40
Volatility 38.01%
Current Volume 1339.5k
Average Volume 20d 2044.3k
What is the price of NVST stocks?
As of December 30, 2024, the stock is trading at USD 19.24 with a total of 1,339,483 shares traded.
Over the past week, the price has changed by +2.34%, over one month by -13.68%, over three months by -2.63% and over the past year by -20.03%.
Is Envista Holdings a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Envista Holdings (NYSE:NVST) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -37.16 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NVST as of December 2024 is 16.80. This means that NVST is currently overvalued and has a potential downside of -12.68%.
Is NVST a buy, sell or hold?
Envista Holdings has received a consensus analysts rating of 3.29. Therefor, it is recommend to hold NVST.
  • Strong Buy: 3
  • Buy: 0
  • Hold: 10
  • Sell: 0
  • Strong Sell: 1
What are the forecast for NVST stock price target?
According to ValueRays Forecast Model, NVST Envista Holdings will be worth about 18.5 in December 2025. The stock is currently trading at 19.24. This means that the stock has a potential downside of -3.69%.
Issuer Forecast Upside
Wallstreet Target Price 21.4 11.3%
Analysts Target Price 40.7 111.4%
ValueRay Target Price 18.5 -3.7%